ArticleFrontiers in neuroscience2026
AD diagnosis model based on fusion of heterogeneous brain imaging and genomic data.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a common neurodegenerative disorder in the elderly population, and early screening can effectively delay the progression of the disease. Mild cognitive impairment (MCI) occurs prior to the onset of AD; however, the accuracy of existing MCI-to-AD prediction methods remains relatively low. Additionally, small sample sizes and high feature dimensions often lead to model overfitting, highlighting the need for effective early screening approaches. To address the aforementioned issues, this study integrated non-paired multi-modal features-including clinical indicators from the ADNI database, blood biomarkers, brain region volume features extracted from MRI, and genetic biomarkers from the GEO database-and proposed a gender-corrected random matching strategy. The Random Forest algorithm was adopted to evaluate this strategy, analyze feature importance, and compare the performance of 9 machine learning algorithms based on the top 40 ranked features. The predictive performance of multi-modal data was superior to that of single-modal data, and the proposed strategy achieved favorable results in early AD screening. 16 specific genetic features (e.g., IFI27, EDF1, RAP2A, KIF5C, SERPINA3, FBXW7, IFITM1, ISG15, PSMB3, APOE4, KCNB1, PSPH, HMGN2, S100A13, IFIT3, and CALM1) and 6 brain region volume features ranked high in terms of importance. When validated using paired datasets from ADNI across the 9 algorithms, ensemble learning models demonstrated significantly stronger fitting capabilities. The non-paired multi-modal fusion approach not only expands the sample size but also enhances the generalization ability and robustness of the model. This provides a theoretical basis for the application of this strategy in the field of small-sample medical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.